• Production capacity of 25 million tests per annum, that can be ramped up further if required
• MDX facility with core production area of around 9,500 sq. ft., is co-located in the Diagnostics facility spread over 50,000 sq. ft.
• Designed with high sensitivity, specificity, and inclusivity, varied molecular test kits are expected to be available in a phased manner, starting from September 2021